Unlike other classes of HDACs, the deacetylation activity of class IV HDAC is relatively weak, and as such, HDAC11 inhibitors might have a greater prospective in obesity treatment because of their relatively fewer side effects (51, 55). This evidence concerns the gene HDAC9 and obesity due to melanocortin 4 receptor deficiency.